January/February 2012

US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus

February 11, 2012

The American Journal of Pharmacy Benefits

Saxagliptin, in combination with metformin, provides a durable, well-tolerated, and cost-effective treatment option for patients with type 2 diabetes mellitus, from a US payer perspective.

Analyzing the Impact of Different Value-Based Insurance Design Programs

February 11, 2012

The American Journal of Pharmacy Benefits

Total 1-year healthcare costs were not significantly reduced by 2 value-based insurance design programs for diabetic patients, although education appeared to improve quality of care.

Evolutions in Outpatient Cancer Care

February 10, 2012

The American Journal of Pharmacy Benefits

Within the last 5 years changes to oncology private practice have led to these clinics aligning themselves with larger entities to maintain their practices.